The Longevity Market Is Shifting From Consumer Wellness to Healthcare Performance
Longevity has largely been a consumer-driven market built around personal optimization. As healthcare organizations face pressure to improve outcomes and manage costs, the opportunity is expanding toward prevention, longitudinal care, and data that can inform clinical and business decisions.
A consumer market is opening new pathways to institutional value
For years, longevity has been marketed primarily as a personal investment: tracking sleep, measuring biological age, purchasing biomarker tests, and using wearables to optimize health. Consumers willing to pay out of pocket have fueled an ecosystem of diagnostics, supplements, coaching, and personalized wellness services.
That consumer market remains important. But the capabilities being developed within it have potential applications beyond individual wellness.
Wearables generate longitudinal data. Diagnostics can identify health risks. Digital platforms can deliver interventions between clinical encounters. Together, these capabilities create opportunities to connect personal health information with clinical decisions, preventive care, and research.
Rock Health identified longevity as an area of digital health innovation to watch entering 2026, alongside developments in wearables, patient phenotyping, and alternative health benefits.¹
The strategic question is whether companies can translate consumer adoption into value that other organizations are willing to fund.
For health plans, that could mean closing preventive care gaps or improving management of chronic conditions. For employers, it could mean expanding access to care and managing benefit costs. For providers, it could mean extending care beyond the clinic. For life sciences companies, it could mean generating useful longitudinal evidence about disease progression and treatment outcomes.
The market opportunity is expanding from selling individual consumers the promise of better health to demonstrating how longevity-related capabilities can improve outcomes and create value across the healthcare ecosystem.
This transition is an emerging opportunity, not a completed market shift. The commercial models, evidence requirements, and funding mechanisms vary substantially across longevity products.
Policy is reinforcing the emphasis on measurable outcomes
One signal of the changing healthcare environment is the growing emphasis on outcomes, digital measurement, and financial accountability.
In September 2026, the Centers for Medicare & Medicaid Services (CMS) announced a partnership with 37 states to rethink Medicaid and Children's Health Insurance Program (CHIP) quality measurement. The Investing in Health Outcomes initiative calls for prioritizing health outcomes, simplifying quality measurement, advancing digital quality measurement, and aligning financial accountability more closely with outcomes.²
The participating states represent approximately 56 million Medicaid and CHIP beneficiaries and accounted for about $701 billion in Medicaid spending in fiscal year 2024. CMS also identified approximately 450 reporting requirements associated with 258 distinct quality measures across Medicaid managed care programs in 42 states.²
The initiative is voluntary. It does not establish a blanket mandate to adopt new technology or guarantee reimbursement for longevity products. Its relevance is the direction it signals: CMS wants quality measurement to focus more on meaningful health outcomes and make better use of timely digital data.
For companies developing preventive and longitudinal health solutions, this creates a reason to examine where their capabilities align with existing healthcare priorities.
Cancer screening offers a concrete example. Breast, cervical, and colorectal cancer screening are established areas of preventive care accountability. Technology that makes screening easier to access may support quality improvement, provided it meets applicable clinical requirements and leads to appropriate follow-up.
The opportunity is not that every longevity product will qualify for reimbursement or improve a CMS quality score. It is that companies addressing established clinical needs may find a clearer institutional value proposition than those selling consumer engagement alone.
Three pathways from consumer innovation to business performance
The market spans different technologies and business models. Three pathways illustrate how capabilities associated with longevity and personal health can address institutional needs.
1. Preventive diagnostics: Turning access into completed care
Consumer diagnostics can make health information more accessible, but their institutional value depends on whether they reach the right populations and lead to appropriate clinical action.
Teal Health illustrates the opportunity to redesign how preventive care is delivered.
Its Teal Wand is an FDA-authorized, prescription-only device for at-home vaginal sample collection for cervical cancer screening. It enables eligible patients to collect a sample at home for high-risk human papillomavirus (HPV) testing, offering an alternative to traditional in-clinic collection.³
The innovation is not simply a consumer diagnostic. It is a different delivery pathway for a recommended preventive service, potentially reducing barriers associated with an in-clinic examination.
For health plans and providers, the business case depends on whether the model reaches people who would otherwise delay or miss screening, improves completion rates, and connects patients to appropriate follow-up care.
There is also an important economic constraint. Teal's published pricing and insurance policies have included limitations on coverage and access for publicly insured populations.⁴ FDA authorization does not establish comprehensive insurance coverage, and a commercially available product is not automatically accessible to every population.
Business implication: Preventive technologies may create institutional value when they close a defined care gap, integrate with existing workflows, and demonstrate sustainable economics. Access, coverage, and follow-up are central to the model, not secondary considerations.
2. Digital care and wearables: Moving from tracking to intervention
Wearables can capture activity, sleep, recovery, and other health signals. But collecting data does not necessarily change health outcomes. Their value becomes more tangible when the technology is connected to a care model that supports intervention and measures progress.
Hinge Health illustrates how digital care can extend beyond the traditional clinic.
Its digital musculoskeletal (MSK) clinic combines digital care delivery with therapeutic support, including Enso, a wearable that delivers electrical stimulation for pain relief. The device is available through Hinge Health's Digital Clinic.⁵
The model differs from selling a standalone consumer wellness wearable. It combines a therapeutic intervention with a digital care service that can be purchased by employers and health plans.
For employers, the potential value includes access to care, benefit costs, and workforce outcomes. For health plans, the relevant questions include clinical improvement, treatment engagement, claims costs, and whether the intervention reduces the need for more expensive care.
The same distinction matters across longevity. A wearable that measures health indicators may be useful to consumers, but institutional buyers need evidence that the data changes decisions or that the intervention improves outcomes.
Business implication: The opportunity is not simply to collect more health data. It is to connect monitoring with an intervention, a defined buyer need, and measurable results.
3. Longitudinal health data: Connecting healthcare and life sciences
A third pathway extends beyond direct care delivery.
Consumer devices, diagnostics, and digital health services can generate data over time that may complement episodic information captured during clinical encounters. When appropriately collected, validated, and governed, these data may support longitudinal health assessment, research, and evaluation of interventions.
For healthcare organizations, potential applications include identifying changes in health, targeting prevention, and supporting ongoing care management. For life sciences companies, longitudinal data may inform studies of disease progression, patient characterization, research recruitment, and treatment outcomes.
However, more data does not automatically produce better evidence. Data must be reliable, clinically relevant, sufficiently representative, and collected under appropriate privacy and consent frameworks. Consumer-generated data may require additional validation before it can support clinical or research decisions.
This creates opportunities for partnerships between consumer health companies, healthcare organizations, and life sciences companies. It does not mean consumer data already has equivalent value across these markets.
Business implication: Companies that can translate longitudinal data into clinically useful insights may have opportunities beyond direct-to-consumer sales. The value will depend on data quality, scientific utility, and the ability to integrate those insights into real decisions.
Institutional demand is changing the commercial equation
The case for institutional value is supported by evidence from the broader digital health purchasing market.
In its 2025 State of Digital Health Purchasing survey, the Peterson Health Technology Institute (PHTI), working with NORC at the University of Chicago, surveyed 309 decision-makers at health plans, employers, and health systems.⁶
The survey found that:
84% of health plans and 79% of health systems had increased investment in digital health solutions over the previous two years.
68% of employers had maintained their spending levels over that period.
Improving access to care was the leading purchasing priority.
Purchasers increasingly sought evidence of clinical outcomes and economic value.
These findings describe digital health purchasing broadly, not longevity specifically. They nevertheless establish a relevant commercial context: institutional buyers are investing in digital solutions while demanding clearer evidence of value.
The distinction between health plans and employers matters. Health plans may purchase or cover solutions to improve member outcomes, quality performance, and healthcare spending. Employers select benefits and digital care offerings based on workforce needs, available plan options, and cost. Self-insured employers also bear more direct responsibility for healthcare claims.
These channels interact. Employers may access digital solutions through their health plans or contract directly with vendors. A company's route to market therefore depends on who controls the budget, who captures the financial benefit, and how the solution fits into existing benefits and care delivery.
For longevity companies, a consumer subscription may be a viable starting point. Institutional adoption requires a different commercial case: a defined population, a measurable need, credible evidence, and a funding mechanism.
How healthcare organizations should evaluate the opportunity
As longevity expands into healthcare delivery and research, organizations need a disciplined way to distinguish compelling consumer products from investments that can generate institutional value.
1. Start with the problem, not the product.
Identify the population, clinical risk, access barrier, or care gap that needs to be addressed. A technology should be evaluated against a defined need, not against a broad promise of healthier aging.
2. Establish the link between intervention and outcome.
Determine whether the solution improves access, changes clinical decisions, supports ongoing care, or produces useful research evidence. Engagement and data collection are intermediate activities, not proof of better outcomes.
3. Identify the buyer and economic beneficiary.
The organization paying for a solution may not capture its full benefit. A health plan, employer, provider, and life sciences company may value different outcomes. The commercial model must reflect those differences.
4. Test the path to scale.
Assess clinical evidence, affordability, coverage, data governance, workflow integration, and the resources required to deliver the intervention. A promising product can still struggle to scale if its economics or distribution model do not fit the intended population.
5. Define measurable success before investing.
Depending on the use case, metrics may include screening completion, clinical improvement, utilization, cost per completed intervention, patient engagement, or research utility. Establish a baseline and determine what evidence would justify expansion.
These steps help organizations identify where longevity-related capabilities align with existing budgets and priorities, and where new partnerships or funding models may be required.
The next phase of longevity will be defined by where value accrues
Longevity is not abandoning its consumer roots. Consumer demand continues to drive innovation in diagnostics, wearables, and personalized health. What is changing is the range of potential applications and buyers.
CMS's quality initiative signals a stronger emphasis on outcomes and digital measurement. PHTI's purchasing research shows that institutional buyers are investing in digital health while seeking evidence of clinical and economic value. Companies such as Teal Health and Hinge Health illustrate how capabilities associated with personal health can be incorporated into preventive care and ongoing treatment models.
Together, these developments suggest an opportunity to connect consumer innovation with institutional priorities. They do not establish that all longevity products will be reimbursed, that consumer data will automatically improve care, or that every solution will deliver a positive financial return.
For healthcare organizations, the opportunity is to identify where these capabilities address meaningful clinical and economic needs. For companies, the challenge is to translate consumer innovation into a product, evidence base, and business model that institutional buyers can justify and scale.
The defining shift is not simply that longevity is becoming more technological. It is that capabilities once marketed primarily for personal optimization may create broader value when connected to healthcare performance, preventive care, and life sciences research.
Sources
Rock Health. Healthcare Innovation at the Turn of 2026: Mapping What's Now and What's Next in Digital Health. December 2025.
Centers for Medicare & Medicaid Services. Investing in Health Outcomes. September 2026. See also: Minemyer, Paige. 37 states partner with CMS on initiative to rethink Medicaid quality measures. Fierce Healthcare, September 2026.
U.S. Food and Drug Administration. Teal Wand De Novo Classification Request, DEN240045. FDA authorization granted May 9, 2025.
Teal Health. Insurance Coverage and Pricing.
Hinge Health. Enso Wearable Technology.
Peterson Health Technology Institute. 2025 State of Digital Health Purchasing.